Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)
What is the SSD — HEDIS® Measure?
Based on current NCQA HEDIS recommendations for best practices, members ages 18 to 64 with schizophrenia, schizoaffective disorder or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.
The following will meet compliance:
Glucose Test or HbA1c Test:
Documentation in the medical record must include a note indicating a glucose test or HbA1c test was performed during the measurement year.
- Order a diabetes screening test every year and build care gap “alerts” in your electronic medical record.
- Follow up with patients to discuss and educate on lab results.
- Coordinate care with other providers.
- Follow up with patients who cancel appointments and reschedule them as soon as possible.
- Encourage shared decision-making by educating patients and caregivers about:- Increased risk of diabetes with antipsychotic medications- Importance of screening for diabetes- Symptoms of new onset diabetes
NCQA HEDIS Population Definition for This Measure:
Population: Members ages 18 to 64 as of December 31 of the measurement year
Line of Business: Medicaid
SSD Antipsychotic Medications
- Aripiprazole lauroxil
- Fluphenazine decanoate
- Haloperidol decanoate
- Paliperidone palmitate
To learn more about your practice’s current HEDIS performance, 2022 HEDIS Value sets for this or other measures, or for assistance in compliance with the HEDIS guidelines, please email BH_HEDISTeam@HorizonBlue.com or visit https://www.horizonblue.com/providers/resources/guidelines/hedis-measurement-year-my-2022-provider-tips-optimizing-hedis-results
Reference: Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD), NCQA HEDIS 2022 Tech Specifications